Medical News

RSS

New scaling law helps predict humans' risk of blast-induced traumatic brain injury

Since the start of the military conflicts in Iraq and Afghanistan, more than 300,000 soldiers have returned to the United States with traumatic brain injury caused by exposure to bomb blasts - and in particular, exposure to improvised explosive devices, or IEDs. Symptoms of traumatic brain injury can range from the mild, such as lingering headaches and nausea, to more severe impairments in memory and cognition.

30 Sep 2014

Seven NIH research contracts awarded to identify novel adjuvant candidates

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.

30 Sep 2014

Review article provides novel insight into brain changes in alcohol-related sleep-wake disturbances

A review article published online in Behavioral Brain Research provides novel insight into changes that happen in the brain as a result of chronic alcohol exposure that can lead to disruptions in the sleep cycle.

30 Sep 2014

State highlights: Calif. health insurers and contraception coverage; Alaska sues Xerox over Medicaid payment systems

Health insurance policies in California will have to cover all federally approved contraceptives for women by 2016 without charging co-payments under legislation signed this week by Gov. Jerry Brown, countering trends in other states and the U.S. Supreme Court. The bill, SB1053 by Sen. Holly Mitchell, D-Los Angeles, expands state laws that required coverage for most birth-control drugs and devices approved by the U.S. Food and Drug Administration. The new law mandates coverage for all FDA-approved contraception, prohibits co-payments and includes managed-care Medi-Cal plans, which are not expressly covered by current laws (Egelko, 9/27).

30 Sep 2014

First-in-kind study evaluates health outcomes of women sexual assault survivors

One in 5 U.S. women experience sexual assault during their lifetime, yet little is known about the experiences and health outcomes of sexual assault survivors. A new study seeks to change that.

30 Sep 2014

Baxter to establish new innovation and R&D center in Cambridge, MA

BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a new lease for approximately 200,000 square feet for 12 years with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc., at 650 East Kendall Street in Cambridge, Massachusetts, which is owned by BioMed Realty through a joint venture with Prudential Real Estate Investors.

From Baxter International Inc. 30 Sep 2014

Neural recordings can be used to forecast spontaneous decisions

You're waiting at a bus stop, expecting the bus to arrive any time. You watch the road. Nothing yet. A little later you start to pace. More time passes. "Maybe there is some problem", you think. Finally, you give up and raise your arm and hail a taxi. Just as you pull away, you glimpse the bus gliding up. Did you have a choice to wait a bit longer? Or was giving up too soon the inevitable and predictable result of a chain of neural events?

30 Sep 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.

30 Sep 2014

Majority of Americans find the health law hard to understand, poll finds

An Associated Press-GfK poll finds that nearly 75 percent of Americans find the overhaul "difficult" and nearly half say it is "very hard" to understand. However, health care remains a key issue. In California, there's an effort, for instance, to target messages that include access to health care in outreach to the much-sought-after female voters. Meanwhile, efforts to undo the health law will remain high on the GOP to-do list if Republcans gain control of the Senate.

30 Sep 2014

Finding ways to rejuvenate "immunological age" of the brain

How the brain ages is still largely an open question - in part because this organ is mostly insulated from direct contact with other systems in the body, including the blood and immune systems. In research that was recently published in Science, Weizmann Institute researchers Prof. Michal Schwartz of the Neurobiology Department and Dr. Ido Amit of Immunology Department found evidence of a unique "signature" that may be the "missing link" between cognitive decline and aging.

30 Sep 2014

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

30 Sep 2014

CFDA clears Elekta's Versa HD radiation therapy system

Following US and European approvals of Elekta's Versa HD™ linear accelerator, the China Food and Drug Administration (CFDA) has cleared the radiation therapy system for sale and marketing in the country.

From Elekta 30 Sep 2014

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Insurers, hospitals hunt for leaders in customer service

It's a great time to be in the hospitality industry ... if you want to go into health care. In case you haven't noticed, health care is becoming more consumer-focused by the day, and in a fight for our business, insurers and health care providers are hunting for executives whose business is customer service -- making sure once we walk through the door, we stay (Gorenstein, 9/26).

30 Sep 2014

Report: Finding care is difficult for some new Medicaid enrollees

State standards for access to care for Medicaid recipients vary widely and are rarely enforced, says a soon-to-be released report by the Health and Human Services Department's inspector general. Meanwhile, Tennessee's governor pursues Medicaid expansion talks, and confusion continues in Pennsylvania about what benefits will be available to enrollees in that state's expansion plan.

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Aspen Dental expands operations with a new dental office in Hermitage, Tennessee

A new Aspen Dental office is opening in Hermitage, TN on Thursday, October 2. Located at 4054 Lebanon Pike, the conveniently located practice will provide dental services that range from implant services and dentures to general dentistry and restoration.

30 Sep 2014

New approach to solve global challenges in food security, emerging diseases and biodiversity loss

Solving global challenges in food security, emerging diseases and biodiversity loss requires evolutionary thinking, argues a new study published online in Science Express that was co-authored by Bruce Tabashnik of the University of Arizona College of Agriculture and Life Sciences.

30 Sep 2014

Apexus secures HRSA contract, continues to serve as prime vendor of 340B Drug Pricing Program

Apexus, LLC, the prime vendor for the 340B Drug Pricing Program, has announced that it has been selected by the Health Resources and Services Administration (HRSA) to continue serving in its role as the prime vendor through September 29, 2019.

30 Sep 2014

Medical News

New scaling law helps predict humans' risk of blast-induced traumatic brain injury

Seven NIH research contracts awarded to identify novel adjuvant candidates

Review article provides novel insight into brain changes in alcohol-related sleep-wake disturbances

State highlights: Calif. health insurers and contraception coverage; Alaska sues Xerox over Medicaid payment systems

First-in-kind study evaluates health outcomes of women sexual assault survivors

Baxter to establish new innovation and R&D center in Cambridge, MA

Neural recordings can be used to forecast spontaneous decisions

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Majority of Americans find the health law hard to understand, poll finds

Finding ways to rejuvenate "immunological age" of the brain

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

CFDA clears Elekta's Versa HD radiation therapy system

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Insurers, hospitals hunt for leaders in customer service

Report: Finding care is difficult for some new Medicaid enrollees

Combination therapy achieves greater progression-free survival, response rates in melanoma

Aspen Dental expands operations with a new dental office in Hermitage, Tennessee

New approach to solve global challenges in food security, emerging diseases and biodiversity loss

Apexus secures HRSA contract, continues to serve as prime vendor of 340B Drug Pricing Program

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Membrane proteins in focus: Turning high-risk targets into routine workflows

Latest News